Apollo acquisition boosts NZ biotech Symansis New Zealand biotech Symansis has purchased Australian company Apollo Cytokine Research for A$500,000 to build on its unique cell signaling science and fast monitor expansion into new worldwide markets. Apollo Cytokine Analysis develops, manufactures and sells the world’s largest commercial range of human being cell-expressed glycoproteins for use in drug analysis, while Symansis creates antibodies that target molecules in growth factor, tension and cytokine signaling pathways. Symansis CEO Dr Peter Foster said the acquisition was a strategic proceed to expand its item offerings and advance both company’s research plan and business plans for growth http://www.cytoxan.net/ .
Apricus Bio awards Neopharm exclusive rights to advertise and offer Vitaros in Israel and Palestinian Territories Apricus Biosciences, Inc. In return, Apricus Bio is entitled to receive up to a total of $4.35 million in up-front, regulatory and sales milestone payments for the merchandise. Further, over the full life of the contract, Apricus Bio shall receive tiered, double-digit royalties predicated on Neopharm’s product sales of the merchandise. .